<DOC>
	<DOCNO>NCT00145041</DOCNO>
	<brief_summary>The purpose study see vincristine , place oil droplet call liposome ( VSLI ) , absorb , distribute ( move around ) excrete body ( pharmacokinetics ) . This study also assess safety VSLI see VSLI slow growth shrink tumor patient metastatic melanoma result liver impairment , relapse previous therapy .</brief_summary>
	<brief_title>Pharmacokinetic Study Liposomal Vincristine Patients With Malignant Melanoma &amp; Hepatic Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : Primary : To assess pharmacokinetics VSLI administer intravenously patient malignant melanoma hepatic dysfunction secondary metastasis . Secondary : To assess safety antitumor activity VSLI population .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients must histologically confirm , surgically nonresectable Stage III IV metastatic cutaneous , mucosal , choroidal melanoma , eligible treatment protocol high priority . Patients must secondary tumor involvement liver confirm CT scan bilirubin level 1.63.0 mg/dL ( National Cancer Institute , Common Terminology Criteria Adverse Events Grade 2 ) ( MD Anderson Cancer Center normal range 01.0 mg/dL ) . Patients must bidimensionally measurable disease . Patients nonchoroidal melanoma must receive prior chemotherapy metastatic disease cytotoxic biological drug . Patients choroidal melanoma may may receive prior chemotherapy metastatic disease cytotoxic biological drug . Patients must Performance Status 0 , 1 , 2 , 3 ( Zubrod Scale ) . Patients must recover adverse effect prior chemotherapy ( include cytotoxic agent biological response modifier ) , and/or irradiation therapy . Patients must absolute neutrophil count ≥1.0 x 10*9/L platelet count ≥100 x 10*9/L . Patients must adequate renal function demonstrate creatinine level ≤2.0 mg/dL . Patients must life expectancy &gt; 8 week . Patients must provide sign informed consent document indicate aware investigational nature study keep policy hospital . Patients treat radiotherapy , chemotherapy , immunotherapy , vaccine treatment and/or alternative anticancer treatment ( include investigational drug ) within 3 week prior study enrollment . Patients treat hepatic chemoembolization within 4 week prior study enrollment . Patients severe hepatic impairment demonstrate plasma ammonia level &gt; 105 mMol/L serum albumin &lt; 2.0 g/dL serum bilirubin &gt; 3.0 mg/dL . Patients serious intercurrent illness . Patients major surgery within 4 week enrollment . Patients advance symptomatic central nervous system ( CNS ) involvement melanoma phenytoin require steroid brain metastasis , spinal cord compression , meningeal `` carcinomatosis '' .Patients asymptomatic stable metastatic CNS disease enrol . Patients receive treatment phenytoin and/or corticosteroid within 1 week enrollment . Patients must remain medication duration treatment phase study . Patients history neurological disorder unrelated chemotherapy ( include familial neurological disease acquire demyelinate disorder ) . Patients Grade 3 great sensory , motor autonomic neuropathy screening cause . Patients receive treatment drug know inhibit induce hepatic drug metabolism cytochrome P4503A4 isoenzymes and/or Pglycoprotein within 1 week study enrollment . Patients must remain drug collection Cycle 4 pretreatment PK sample . Patients past current history liver parenchymal hepatobiliary disease unrelated cancer ( include limit condition liver cirrhosis , acute/chronic hepatitis , ascend cholangitis , etc ) . Patients pregnant lactate . Females childbearing potential must negative urine blood pregnancy test screening . Both men woman must practice adequate method birth control duration study . Acceptable method birth control include use intrauterine device ( IUD ) , oral contraceptive pill , implant , transdermal , injected contraceptive , barrier method spermicide , abstinence . Patients unable return follow reevaluation assessment response VSLI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>